Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personalized Medicine Needs Personalized Advocacy To Advance, PhRMA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

CEO Castellani says message has to be specifically tailored to payers, patient advocates and regulators.
Advertisement

Related Content

CER Dissemination: PCORI Could Help Raise The Bar For Clinical Guidelines
PDUFA V Agreement Appears Set Between FDA And Industry
PDUFA V Agreement Appears Set Between FDA And Industry
Regulatory Workaround, Not Statutory Changes, Better For Personalized Medicine Development, FDA Commissioner Hamburg Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS072365

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel